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Introduction {#sec001}
============

Bacterial infectious diseases are complicated by antimicrobial resistance and global concerns with the clinical impact of resistance is redefining antimicrobial utilization \[[@pone.0210154.ref001],[@pone.0210154.ref002]\]. In addition to clinical outcomes, microbiological measurements continue to contribute to novel data on drug use for treatment and bacterial eradication. Optimization of therapy needs to consider clinical outcomes and antimicrobial resistance prevention during therapy. Guideline documents for antimicrobial therapy of human infectious diseases give consideration of antimicrobial agents with a reduced likelihood for resistance selection to be important when making therapeutic choices \[[@pone.0210154.ref003],[@pone.0210154.ref004]\]. Such an observation clearly impacts economic costs and adds substantially to treatment costs.

In pigs, respiratory disease is amongst the most important health concerns for swine producers. Swine respiratory disease has been previously recognized as the main pathogen-identified cause of swine mortality accounting for deaths in \~44% of nursing pigs and \~61% of grown finished pigs \[[@pone.0210154.ref005]\]. Porcine respiratory disease complex (PRDC) is a multifactorial clinical entity describing pneumonia in pigs where multiple etiologies contribute to the pathogenesis leading to clinical disease \[[@pone.0210154.ref005]\]. This complex etiology and pathogenesis may include one or more viruses, *Mycoplasma hyopneumoniae*, opportunistic and pathogenic bacteria. *P*. *multocida* is an important pig pathogen and is carried by a large number of animals and transmission is mostly by aerosols \[[@pone.0210154.ref006],[@pone.0210154.ref007]\]. Following invasion, *P*. *multocida* multiplies quickly, liberates toxins and causes necrotic lesions in lung tissue. *A*. *pleuropneumoniae* is highly contagious and causes an acute or chronic fibro-haemorrhagic necrotising pneumonia \[[@pone.0210154.ref008]\]. Ceftiofur (beta-lactam), enrofloxacin (fluoroquinolone), florfenicol (phenol), tilmicosin (macrolide) and tulathromycin (triamalide) are commonly used for swine infections.

Antimicrobial susceptibility or resistance is determined *in vitro* by measuring the minimum inhibitory concentration (MIC) utilizes a bacterial inoculum of 10^5^ colony forming units per millilitre (cfu/ml) \[[@pone.0210154.ref009]\]. Previous publications for human infectious diseases reported substantially higher bacterial densities (i.e. 10^7^−10^9^ cfu/ml or higher) during infections such as meningitis, pneumonia and from protected brush specimens from patients with an acute bacterial exacerbation of their chronic lung disease \[[@pone.0210154.ref010]--[@pone.0210154.ref013]\]. Additionally, McVey and Kusak studied lung, tonsil and trachea tissues from calves with bronchopneumonia and reported 12% of samples had \>10^8^ cfu/g and 50% of specimens hads \>10^5^ cfu/g with *Mannheimia haemolytica* being the most common organism recovered \[[@pone.0210154.ref014]\]. Given the substantially higher bacterial densities in infection than tested in an MIC assay, it begs the question as to the true dynamics of bug/drug interactions when higher bacterial densities are encountered. The mutant prevention concentration (MPC) describes a drug concentration threshold or lowest drug concentration blocking growth of mutant bacterial sub-populations \[[@pone.0210154.ref015],[@pone.0210154.ref016]\] that spontaneously arise in bacterial densities of 10^7^−10^9^ cfu--densities seen with infection. Antibiotic drug concentrations insufficiently inhibiting mutant cell growth result in selective amplification of bacterial cells with reduced drug susceptibility \[[@pone.0210154.ref016],[@pone.0210154.ref017]\]. In a study with fluoroquinolones and the human pathogen *Streptococcus pneumoniae*, differences were seen between fluoroquinolone compounds and macrolide compounds and MPC values \[[@pone.0210154.ref018],[@pone.0210154.ref019]\]. Published MPC studies have been completed with human pathogens and fluoroquinolones, macrolides and many other drug classes \[[@pone.0210154.ref017],[@pone.0210154.ref018],[@pone.0210154.ref020]--[@pone.0210154.ref022]\]. Fluoroquinolones used in veterinary medicine were previously tested by MPC against *E*. *coli* and *Staphylococcus pseudintermedius* and MPC measurements with *M*. *haemolytica* have been reported for ceftiofur, enrofloxacin, florfenicol, tilmicosin and tulathromycin showing differences between compounds in their ability to prevent mutant growth at clinically relevant concentrations \[[@pone.0210154.ref017],[@pone.0210154.ref023],[@pone.0210154.ref024]\].

Here we report on testing of swine clinical isolates of *A*. *pleuropneumoniae*, *P*. *multocida* and *S*. *suis* by MPC to ceftiofur, enrofloxacin, florfenicol, tilmicosin and tulathromycin to determine antimicrobial drug concentrations blocking the most resistant bacterial organisms in high density cultures. Observations reported here may inform thinking on antimicrobial use to affect clinical cure, minimize resistance selection during therapy and pharmacokinetic/pharmacodynamic modelling.

Materials and methods {#sec002}
=====================

Bacterial strains {#sec003}
-----------------

Bacterial pathogens collected from swine in the U.S.A were used: *A*. *pleuropneumoniae* (n = 67), *P*. *multocida* (n = 73), *S*. *suis* (n = 59). These organisms were generously provided by Dr. Ching Ching Wu from the Indiana Animal Disease Diagnostic Laboratory, Purdue University, West Lafayette, Indiana. Bacterial strains were identified by Vitek II (bioMerieux, St. Laurent, QC), matrix assisted laser desorption ionization-time of flight (MALDI-TOF) (bioMerieux, St. Laurent, QC) and/or biochemical tests as summarized in the Manual of Clinical Microbiology \[[@pone.0210154.ref025]\]. Individual strains were stored at -70°C in skim milk. For MIC testing, bacteria were thawed and subcultured two times on blood agar (tryptic soy agar containing 5% sheep red blood cells) (BA) plates with incubation for 18--24 hours at 35--37°C in oxygen (O~2~). Bacterial strains included in the study needed to be susceptible (where breakpoints exist) to the drugs tested by interpretative criteria as per the Clinical and Laboratory Standards Institute (CLSI) \[[@pone.0210154.ref009]\].

Antimicrobial compounds {#sec004}
-----------------------

Enrofloxacin was provided by Bayer Animal Health, Shawnee Mission, Kansas esd prepared as per manufacturer's instructions. Ceftiofur, florfenicol, tilmicosin and tulathromycin were purchased commercially through the Western College of Veterinary Medicine Pharmacy at the University of Saskatchewan and reconstituted based on manufacturer's directions. Fresh stock solutions or those prepared from frozen samples (-70°C) were used. For quality control, the following American Type Culture Collection (ATCC) control strains were included in each susceptible assay to ensure performance of the susceptibility assays: *Enterococcus faecalis* ATCC 29212, *Pseudomonas aeruginosa* ATCC 27853, *E*. *coli* ATCC 25222, *Staphylococcus aureus* ATCC 29213. MIC values needed to be within acceptable ranges for each organism/drug.

MIC measurements {#sec005}
----------------

MIC testing was based on the recommended CLSI procedure \[[@pone.0210154.ref009]\]. Briefly, Mueller-Hinton broth (MHB) containing two-fold concentration of drug was added to 96-well micro-dilution trays. A 0.5 McFarland density of *A*. *pleuropneumoniae*, *P*. *multocida* and *S*. *suis* was further diluted to 5 x 10^5^ cfu/ml, added to the microdilution tray containing drug and incubated for 18--24 hours (35--37°C) in O~2~. The MIC was interpreted as the lowest drug concentration inhibiting visible growth. The designation of MIC~50~ and MIC~90~ are determined by calculating the drug concentration inhibiting 50% or 90% of strains respectfully by starting from the lowest MIC or MPC values.

MPC testing {#sec006}
-----------

MPC testing was adapted from the method published for *S*. *pneumoniae* and previously reported for *Mannheimia haemolytica* \[[@pone.0210154.ref018],[@pone.0210154.ref024]\]. Starter cultures for *A*. *pleuropneumoniae* and *P*. *multocida* were inoculated on 5 BA plates per isolate to produce confluent growth and then incubated at 35--37°C for 18--24 hours in O~2~. Starter cultures for *S*. *suis* isolates were on 5 chocolate agar plates with incubation for 18--24 hours at 35-37°C in O~2~ following which the plate surfaces were swabbed to remove bacterial growth and transferred to 100 ml of brain heart infusion broth containing nicotinamide adenine dinucleotide (NAD) (*A*. *pleuropneumoniae*) or MHB (*P*. *multocida*) or Veterinary Fastidious Medium (MHB plus 3% laked horse blood) (Trek Diagnostic System, Cleveland, Ohio) (*S*. *suis*) and incubated as described. Following incubation, turbidity measurements verified cell densities of 3 x 10^8^ cfu/ml. Centrifugation at 5000 x G for 3 minutes at 4°C was used to concentrate bacteria following which the pellet was added to 3 ml of fresh medium. Drug containing agar plates (7 drug concentrations in doubling dilution) were inoculated with 200 ul (10^10^ cfu) of bacterial suspension and incubated for 24 hours at 35-37°C in O~2~ and screened for growth. Plates were reincubated for an additional 24 hours and the final reading recorded. The MPC value was the lowest drug concentration blocking growth. Drug concentrations tested were ceftiofur 0.06 to 4 mg/L, enrofloxacin 0.004 to 2 mg/L, florfenicol 0.5 to 32 mg/L, tilmicosin 0.5 to 64 mg/L, tulathromycin 0.25 to 16 mg/L. The designation of MPC~50~ and MPC~90~ are by calculating the drug concentration inhibiting 50% or 90% of strains respectfully by starting from the lowest MIC or MPC values.

Results {#sec007}
=======

MIC and MPC data for *A*. *pleuropneumoniae* strains and the 5 drugs is shown in [Table 1](#pone.0210154.t001){ref-type="table"}. Drug concentrations inhibiting 50% and 90% respectively of bacterial strains is the MIC~50~ and MIC~90~ or MPC~50~ and MPC~90~ depending on the *in vitro* measurement. For ceftiofur, MIC~range,~ MIC~50~ and MIC~90~ and values were ≤0.016--0.063 mg/L, 0.016 mg/L and 0.031 mg/L; for enrofloxacin ≤0.016 mg/L, \<0.016 mg/L, and ≤0.016; for florfenicol 0.5--1 mg/L, 0.25 mg/L and 0.5 mg/L; for tilmicosin 1--8 mg/L, 2 mg/L and 4 mg/L; for tulathromycin 0.5--8 mg/L, 1 mg/L and 2 mg/L. A comparison of MPC values are also shown in [Table 1](#pone.0210154.t001){ref-type="table"} for the *A*. *pleuropneumoniae* strains. The MPC~range~, MPC~50~ and MPC~90~ values were as follows respectively for each agent: ceftiofur ≤0.016--1 mg/L, 0.063 mg/L, 0.5 mg/L; enrofloxacin 0.063--0.5 mg/L, 0.125 mg/L, 0.5 mg/L; florfenicol 0.25--4 mg/L, 0.5 mg/L, 2 mg/L; tilmicosin 8--64 mg/L, 32 mg/L, 32 mg/L; tulathromycin 8--32 mg/L, 32 mg/L, 32 mg/L.

10.1371/journal.pone.0210154.t001

###### MIC and MPC values for 67 *A*. *pleuropneumoniae* isolates from swine.

![](pone.0210154.t001){#pone.0210154.t001g}

  Drug                   MIC/MPC Distribution Values (mg/L)                                                              
  ---------------------- ------------------------------------ ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- --- ---------------
  **MIC Distribution**   **MIC**~**50/90**~                                                                              
  Ceftiofur              46                                   19   2                                                     ≤0.016/0.031
  Enrofloxacin           67                                                                                              ≤0.016/≤0.016
  Florfenicol                                                                30   36   1                                 0.5/0.5
  Tilmicosin                                                                           2    49   15   1                  2/4
  Tulathromycin                                                                   5    54   7         1                  1/2
  **MPC Distribution**   **MPC**~**50/90**~                                                                              
  Ceftiofur              2                                    15   26   11   5    2    6                                 0.063/0.5
  Enrofloxacin                                                     25   18   14   10                                     0.125/0.5
  Florfenicol                                                                1    48   9    6    3                       0.5/2
  Tilmicosin                                                                                          11   13   41   2   32/32
  Tulathromycin                                                                                       1    10   56       32/32

[Table 2](#pone.0210154.t002){ref-type="table"} summarizes MIC and MPC data for the *P*. *multocida* strain tested against the 5 drugs investigated. The MIC~range~, MIC~50~ and MIC~90~ values respectively for each agent were as follows: ceftiofur ≤0.016--0.031 mg/L, ≤0.016 mg/L, ≤0.016 mg/L; enrofloxacin ≤0.016 mg/L, ≤0.016 mg/L, ≤0.016 mg/L; florfenicol 0.25--1 mg/L, 0.5 mg/L, 0.5 mg/L; tilmicosin 1--8 mg/L, 2 mg/L, 4 mg/L; tulathromycin 0.063--1 mg/L, 0.25 μ/ml, 0.5 mg/L. MPC~range~, MPC~50~ and MPC~90~ values respectively were as follows: ceftiofur 0.031--0.5 mg/L, 0.125 mg/L, 0.25 mg/L; enrofloxacin ≤0.016--0.125 mg/L, 0.063 mg/L, 0.125 mg/L; florfenicol 0.25--2 mg/L, 1 mg/L, 1 mg/L; tilmicosin 2-≥64 mg/L, 8 mg/L, 16 mg/L; tulathromycin 0.5--8 mg/L, 1 mg/L, 1 mg/L.

10.1371/journal.pone.0210154.t002

###### MIC and MPC values for 73 *P*. *multocida* isolates from swine.

![](pone.0210154.t002){#pone.0210154.t002g}

  Drug                   MIC/MPC Distribution Values (mg/L)                                                             
  ---------------------- ------------------------------------ ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- --- --- ---------------
  **MIC Distribution**   **MIC**~**50/90**~                                                                             
  Ceftiofur              72                                   1                                                         ≤0.016/≤0.016
  Enrofloxacin           73                                                                                             ≤0.016/≤0.016
  Florfenicol                                                                21   48   4                                0.5/0.5
  Tilmicosin                                                                           7    35   25   4                 2/4
  Tulathromycin                                                    1    9    38   21   4                                0.25/0.5
  **MPC Distribution**   **MPC**~**50/90**~                                                                             
  Ceftiofur                                                   14   16   22   17   1                                     0.125/0.25
  Enrofloxacin                                                19   34   15                                              0.063/0.125
  Florfenicol                                                                1    12   59   1                           1/1
  Tilmicosin                                                                                2    13   38   15   4   1   8/16
  Tulathromycin                                                                   19   47   3    3    1                 1/1

A total of 59 *S*. *suis* strains ([Table 3](#pone.0210154.t003){ref-type="table"}) had MICs of 0.031 to 2 mg/L for ceftiofur with an MIC~50~ and MIC~90~ of 0.063 mg/L and 1 mg/L; for enrofloxacin values ranged from 0.063-≥4 mg/L with an MIC~50~ of 0.05 mg/L and an MIC~90~ of 0.5 mg/L. For florfenicol, MICs ranged from 2-≥4 mg/L and a MIC~50~ and MIC~90~ of ≥4 mg/L. All 59 strains had MIC values to tilmicosin and tulathromycin of ≥4 mg/L with MIC~50~ and MIC~90~ values of 8 mg/L. For MPC testing, 16 *S*. *suis* strains with MIC to ceftiofur of 0.063--0.5 mg/L were tested and MPC values were 0.124 (n = 7), 0.25 (n = 5) and 0.5 (n = 4) mg/L with MPC~50~ and MPC~90~ values of 0.25 mg/L and 0.5 mg/L. By comparison, 12 *S*. *suis* strains with MIC to enrofloxacin of 0.125--0.25 mg/L had MPC values of 0.25 (n = 1), 0.5 (n = 1), 1 (n = 8), 2 (n = 1) and 4 mg/L (n = 1) with an MPC~50~ and MPC~90~ of 1 mg/L. MPC testing against florfenicol, tilmicosin and tulathromycin was not done due to the high (≥4mg/L) MIC values.

10.1371/journal.pone.0210154.t003

###### Comparative MIC values for 59 *S*. *suis* strains collected from swine.

![](pone.0210154.t003){#pone.0210154.t003g}

  Drug            MIC Distribution Values (mg/L)   MIC~50/90~                                                                         
  --------------- -------------------------------- ------------ --- ---- ---- --- ---- ----------------------------------------- ---- ----------
  Ceftiofur       6                                29           3   1    3    3   4    1                                         9    0.063/1
  Enrofloxacin                                     1            4   28   23   1        2                                              0.25/0.5
  Florfenicol                                                                     29   30[\*](#t003fn001){ref-type="table-fn"}        ≥4/≥4
  Tilmicosin                                                                  1                                                  58   ≥4/≥4
  Tulathromycin                                                                                                                  59   ≥4/≥4

**\***≥4 mg/L

By MPC testing, no strains of *A*. *pleuropneumoniae* or *P*. *multocida* had values ≥2 mg/L for ceftiofur. For enrofloxacin, no strains of *P*. *multocida* had MPC values ≥0.25 mg/L, however, 10 strains of *A*. *pleuropneumoniae* had MPCs of 0.5 mg/L (breakpoint ≤0.25 mg/L). Three strains of *A*. *pleuropneumoniae* had MPC values of 4 mg/L to florfenicol (≤2 mg/L breakpoint). For tilmicosin (≤16 mg/L breakpoint) 43/67 (64.1%) *A*. *pleuropneumoniae* strains had a MPC value of ≥32 mg/L compared to 5/73 (6.8%) *P*. *multocida* strains with MPC values ≥32 mg/L. For tulathromycin with a ≤64 mg/L breakpoint for *A*. *pleuropneumoniae* and ≤16 mg/L breakpoint for *P*. *multocida*, no *A*. *pleuropneumoniae* strains had MPC values of ≥64 mg/L and no strains of *P*. *multocida* had MPC values ≥16 mg/L.

Discussion {#sec008}
==========

This is the first report of MPC results for *A*. *pleuropneumoniae* and *P*. *multocida* swine pathogen clinical isolates tested against veterinary approved drugs including fluoroquinolones, beta-lactams, phenols, macrolides and triamalide drug classes; MPC values were lowest for ceftiofur and enrofloxacin. Lei *et al* previously reported an MPC value for florfenicol against *S*. *suis* strains of 3.2 μg/ml and the MIC~90~ was 2 μg/ml \[[@pone.0210154.ref026]\]. Florfenicol MPC values against the *S*. *suis* strains in our study were not determined nor were those for tilmicosin or tulathromycin due to the high MIC values. As with previous publications with human and veterinary pathogens and antimicrobials, MPC values were higher than MIC values \[[@pone.0210154.ref017],[@pone.0210154.ref027]\]. This study adds further to the growing body of MPC data and further confirms MPC measurements for important veterinary pathogens and antimicrobial agents. Dorey *et al* recently commented on the lack of published data for swine pathogens detailing MIC, MPC and MSW and how such data was necessary for PK/PD modelling studies \[[@pone.0210154.ref028]\].

The *in vitro* activity of antimicrobials used in swine on *A*. *pleuropneumoniae*, *P*. *multocida* and *s*.*suis* has been previously reported. Salmon *et al* and Portis *et al* reported MIC~50~ and MIC~90~ values for ceftiofur and enrofloxacin that were consistent overall with values in this report, particularly for the *A*. *pleuropneumoniae* and *P*. *multocida* strains \[[@pone.0210154.ref029],[@pone.0210154.ref030]\]. Florfenicol, tilmicosin and tulathromycin MIC~90~ values were higher in the publication of Portis *et al* than in our report and this most likely is due to that study being more a surveillance report whereas in our study we selected strains with MICs at or below susceptibility breakpoints where available. Shin *et al* reported on MIC~90~ values of 0.5 μg/ml for florfenicol tested against *A*. *pleuropneumoniae* and *P*. *multocida* strains \[[@pone.0210154.ref031]\].

MPC investigations with various classes of antimicrobial agents have been reported \[[@pone.0210154.ref017],[@pone.0210154.ref022],[@pone.0210154.ref024],[@pone.0210154.ref032]\] despite an earlier publication suggesting MPC measurements only apply to fluoroquinolones and not aminoglycosides, macrolides or beta-lactams \[[@pone.0210154.ref033]\]. For example, Metzler *et al* compared MPC values for azithromycin, clarithromycin and erythromycin against *S*. *pneumoniae* strains and showed clarithromycin was statistically less likely to select for organism with reduced susceptibility and azithromycin was statistically more likely \[[@pone.0210154.ref019]\].

A number of publications have investigated pharmacological modelling of the mutant selection window and dosing strategies that fall within or outside of the MSW \[[@pone.0210154.ref034]--[@pone.0210154.ref037]\]. The mutant selection window (MSW) is bordered by the MIC (lower drug concentration) and the MPC (upper drug concentration). Firsov *et al* tested the MSW hypothesis using *S*. *aureus*, daptomycin and vancomycin and found that selection of organisms resistant to 2X and 4X the MIC of either drug occurred with antibiotic concentrations falling within the MSW \[[@pone.0210154.ref036]\], a finding supporting the MSW hypothesis. Similar findings were reported with fluoroquinolones and *S*. *aureus* strains \[[@pone.0210154.ref034]\]. From investigators with *Streptococcus pneumoniae* and moxifloxacin, resistance was selected at drug concentrations falling within the MSW and a more recent report found that time within the MSW was an appropriate prediction of bacterial resistance \[[@pone.0210154.ref035],[@pone.0210154.ref038]\]. In a report from testing gatifloxacin and *S*. *pneumoniae* in a rabbit empyema model, dosing of gatifloxacin to remain within the MSW for ≥40% of the dose resulted in mutant subpopulation amplification \[[@pone.0210154.ref039]\].

We \[[@pone.0210154.ref024]\] and others \[[@pone.0210154.ref040],[@pone.0210154.ref041]\]have previously commented on some of the characteristics of macrolide and macrolide like compounds (azalides, triamilides) in human and veterinary medicine. In particular, all such agents have low serum drug concentrations and lung concentrations vary when considering epithelial lining fluid drug concentrations versus alveolar macrophage drug concentrations. Our susceptibility results for tulathromycin appear consistent with results from previous measurements with *M*. *haemolytica* and more recently *P*. *multocida* \[[@pone.0210154.ref024],[@pone.0210154.ref042]\]. In this study, the MIC~90~ values for tilmicosin were 4 mg/L against the *A*. *pleuropneumoniae* and *P*. *multocida* strains as compared to 2 and 0.5 mg/L respectively for tulathromycin. MIC values in excess of 0.5 mg/L are above achievable or sustainable blood concentrations for tilmicosin and tulathromycin ([www.zoetis.com](http://www.zoetis.com/)).

For both tilmicosin and tulathromycin, MPC values were ≥8 mg/L for all strains of *A*. *pleuropneumoniae*. For tilmicosin MPC values were ≥2 mg/L for all *P*. *multocida* strains as compared to ≥0.5 mg/L for tulathromycin. For those compounds and considering the MSW and MIC~90~ and MPC~90~ values, the MSW for tilmicosin and *A*. *pleuropneumoniae* would range from 4 to 32 mg/L (8-fold difference) and for *P*. *multocida* from 4 to 16 mg/L (4-fold difference). By comparison, for tulathromycin and *A*. *pleuropneumoniae* the MSW would range from 2--32 mg/L (16-fold difference) and for *P*. *multocida* the MSW was narrow being the same or within a 2-fold difference. For individual strains, the MSW may be narrower if the fold difference between the measured MIC and MPC values were less.

In swine lungs, tulathromycin concentrations peak at approximately 3.5 mg/L \[[@pone.0210154.ref043],[@pone.0210154.ref044]\]. Tulathromycin neutrophil and alveolar macrophage concentrations in pigs were 16.6 and 8.1 x respectively the extracellular fluid concentration \[[@pone.0210154.ref044],[@pone.0210154.ref045]\]. Based on MIC and MPC values reported in this study, pulmonary drug concentrations for tulathromycin would fall within the MSW for the *A*. *pleuropneumoniae* and *P*. *multocida* strains. For the *A*. *pleuropneumoniae* strains, all 67 strains had MPC values (8--32 mg/L) above the maximum pulmonary drug concentration of 3.5 mg/L and for *P*. *multocida* strains 4/73 (5.4%) had MPC values above the maximum pulmonary drug concentration. Based on the data of Benchaoui *et al*, time within the MSW for tulathromycin for *A*. *pleuropneumoniae* and *P*. *multocida* could be as long as 15 days due to the long elimination half-life.\[[@pone.0210154.ref043]\] Given the achievable serum and pulmonary concentrations for tulathromycin, the susceptible breakpoints of 16 mg/L and 64 mg/L for *P*. *multocida* and *A*. *pleuropneumoniae* respectively is puzzling.

For the remaining drugs tested and considering the MSW, blood levels of ceftiofur exceed the MSW for 48--6 hours but we did not conduct testing to account for the high protein binding (\>90%) associated with this compound. Others have shown the protein binding in excess of 60% elevates MIC values *in vitro* when protein is included in the susceptibility assays \[[@pone.0210154.ref046]--[@pone.0210154.ref048]\]. How this observation translates clinically is not fully understood. Enrofloxacin (7.5 mg/kg) blood levels exceed the MSW for \~12--18 hours for isolates with MPCs of 0.5 mg/L. In our study, 71% of isolates had MPC values to enrofloxacin ≤0.5 mg/L. Considering florfenicol, blood concentrations fall within the MSW, however, MPC values of ≤4 mg/L were seen for the majority of isolates tested and for these, drug concentration would exceed the MSW for \~6 hours.

The MPC defines an *in vitro* measurement using high density bacterial populations that are representative of bacterial burdens present in acute infections. The MSW provide a drug concentration range where therapeutic drug concentrations falling and remaining in this range, based on approved dosage may allow for selective amplification of the least susceptible cells in the population. Dosing to achieve or exceed the MPC and hence the MSW prevents growth of bacterial cells with reduced susceptibility, however, dosing to exceed the MSW does not appear possible for all bug-drug combinations. In our study, enrofloxacin and ceftiofur had lower MIC and MPC values than did the other drugs. MPC principles may optimize therapy and impact resistance while providing valuable data for pharmacokinetic and pharmacodynamic modelling. Optimization of therapy while minimizing the potential for antimicrobial resistance are major principals for antimicrobial stewardship \[[@pone.0210154.ref049]\].

We thank Deb Hills for excellent clerical assistance. This study was funded, in part, by an investigator initialized unrestricted research grant from Bayer Animal Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. There was no additional external funding received for this study.

[^1]: **Competing Interests:**The authors have declared that no competing interests exist.
